Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Amvuttra (vutrisiran) / Alnylam
HELIOS-A, NCT03759379 / 2018-002098-23: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)	Active, not recruiting	3	164	Europe, Canada, Japan, US, RoW	Patisiran, ONPATTRO, ALN-TTR02, Vutrisiran, ALN-TTRSC02, AMVUTTRA	Alnylam Pharmaceuticals	Amyloidosis, Hereditary, Transthyretin Amyloidosis	11/20	10/26
HELIOS-B, NCT04153149 / 2019-003153-28: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy	Active, not recruiting	3	655	Europe, Canada, Japan, US, RoW	Vutrisiran, ALN-TTRSC02, Sterile Normal Saline (0.9% NaCl)	Alnylam Pharmaceuticals	Transthyretin Amyloidosis (ATTR) With Cardiomyopathy	05/24	12/26
NCT06679946: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy	Enrolling by invitation	3	800	Europe, US, RoW	Vutrisiran, ALN-TTRSC02, AMVUTTRA®	Alnylam Pharmaceuticals	Transthyretin Amyloidosis (ATTR) With Cardiomyopathy	06/28	06/28
MyocardON-TTR, NCT05873868: Myocardial Effects in Patients with ATTRv with Polyneuropathy Treated with Patisiran or Vutrisiran	Recruiting	N/A	20	Europe	Six minutes walk test, Kansas City questionnaire, COMPASS31 self questionnaire	Rennes University Hospital	Transthyretin Amyloidosis, Amyloidosis, Hereditary	02/26	07/26